Kevin Lind is President and Chief Executive Officer of Longboard Pharmaceuticals, Inc. (LBPH). The company reported total compensation of $2,053,804 for fiscal year 2023.
| Salary | $610,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $986,934 |
| Non-equity incentive plan | $442,860 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,010 |
| Total | $2,053,804 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Longboard Pharmaceuticals, Inc. filed April 12, 2024, accession 0000950170-24-044023.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2023 | President and Chief Executive Officer | $610,000 | $0 | $0 | $986,934 | $442,860 | $0 | $14,010 | $2,053,804 |
| FY2022 | President and Chief Executive Officer | $572,000 | $0 | $0 | $544,070 | $377,520 | $0 | $12,325 | $1,505,915 |
Totals as disclosed in each year's own compensation disclosure for Longboard Pharmaceuticals, Inc..
| Named executive officer | Role | FY2023 total |
|---|---|---|
| Kevin Lind this page | President and Chief Executive Officer | $2,053,804 |
| Randall Kaye | Executive Vice President and Chief Medical Officer | $1,161,067 |
| Brandi Roberts | Executive Vice President and Chief Financial Officer | $1,025,200 |
The company's named executive officers for fiscal year 2023, and what it reported for each. See the full Longboard Pharmaceuticals, Inc. compensation brief.
Kevin Lind's compensation sits inside Longboard Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Longboard Pharmaceuticals, Inc. (LBPH) compensation brief